Valneva SE (FR:VLA)
:VLA
Want to see FR:VLA full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.07Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Negative
The call contained material positive programmatic and strategic news (notably the encouraging Lyme Phase III efficacy with planned regulatory submissions by Pfizer, clear execution on Chikungunya access in Brazil and progress on Shigella) and decisive management actions (cash preservation and a 25%–35% operating expense reduction target). However, near‑term financial performance was weak: revenues and key product sales declined sharply (~37% total revenue decline), gross margins deteriorated substantially (commercial and IXIARO margins down ~17–22 percentage points), and the net loss widened materially. Manufacturing transition costs, one‑offs (failed batches, inventory provisions), FDA observations on Almeida and travel market risks add execution and revenue downside in the near term. Overall, the negative financial trends and operational risks outweigh the programmatic upside at this stage.Company Guidance
Lyme Phase III Efficacy and Regulatory Path
Strong efficacy observed in Phase III: overall vaccine efficacy >70%; first prespecified statistical criterion not met but second prespecified analysis met with 95% CI lower bound above 20. The vaccine was well tolerated with no safety concerns; Pfizer is planning submissions to regulatory authorities.
Unique Market Opportunity for Lyme Vaccine
VLA15 (LB6V) is the only Lyme vaccine candidate at this stage in ~30 years, with broad serotype coverage for North America and Europe (addressing ~90M and >200M people in high‑risk areas) and significant unmet medical need (reported ~500,000 US cases and >100,000 Europe annually).
Cash Position and Financing
Total cash and cash equivalents at end of March 2026: EUR 105 million (down slightly from EUR 110 million at fiscal year end); cash figure excludes proceeds from a successful reserved offering completed in April 2026, which will further improve liquidity.
Operational Cost Reduction Program
Comprehensive restructuring initiated in April 2026 targeting a global workforce reduction of ~10%–15% and an overall operating expense reduction of ~25%–35% versus 2025 to contain cash burn and improve operating leverage.
IXCHIQ Progress and Brazil Campaign
Active IXCHIQ (Chikungunya) activities: over 30,000 people vaccinated in Brazil pilot campaign (targeting 20%–40% coverage in 18–59 adults across municipalities) and aim >100,000; locally produced Butantan‑chik achieved licensure in Brazil — major access/manufacturing milestone.
Shigella Program Advancement
Tetravalent Shigella candidate progressing with two ongoing studies (children in Africa and a controlled human infection model); readouts expected over the summer and program targets a global market expected north of USD 0.5 billion annually.
Disciplined R&D and SG&A Trends
R&D spend stable at EUR 15.2 million (Q1 2026); marketing & distribution decreased to EUR 7.0 million from EUR 10.4 million (Q1 2025); G&A decreased to EUR 8.2 million from EUR 9.0 million, indicating early expense discipline aligned with restructuring.
Manufacturing Network Progress Outside U.S.
Manufacturing transfer to the Almeida facility completed with regulatory approvals from non‑U.S. authorities; local manufacturing partnerships and network expansion in endemic countries are advancing to support access.
FR:VLA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:VLA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | €2.53 | €2.58 | +1.90% |
Mar 18, 2026 | €4.72 | €4.81 | +1.91% |
Nov 20, 2025 | €3.74 | €3.77 | +0.91% |
Aug 12, 2025 | €3.64 | €3.96 | +8.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Valneva SE (FR:VLA) report earnings?
Valneva SE (FR:VLA) is schdueled to report earning on Aug 11, 2026, TBA (Confirmed).
What is Valneva SE (FR:VLA) earnings time?
Valneva SE (FR:VLA) earnings time is at Aug 11, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Valneva SE stock?
The P/E ratio of Valneva is N/A.
What is FR:VLA EPS forecast?
FR:VLA EPS forecast for the fiscal quarter 2026 (Q2) is -0.07.